A5011414495- Amyloidosis: Diagnosis, Treatment, Outcomes
- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Mast cells and histamine
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Glycosylation and Glycoproteins Research
- Chronic Myeloid Leukemia Treatments
- Neuroendocrine Tumor Research Advances
- Urticaria and Related Conditions
- Parathyroid Disorders and Treatments
- Protein Kinase Regulation and GTPase Signaling
- Autoimmune Bullous Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pancreatitis Pathology and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Balance, Gait, and Falls Prevention
- Parkinson's Disease Mechanisms and Treatments
- Cancer Mechanisms and Therapy
- Cerebral Palsy and Movement Disorders
- Galectins and Cancer Biology
- Intestinal Malrotation and Obstruction Disorders
- Diabetes and associated disorders
- Drug Transport and Resistance Mechanisms
University of Insubria
2024-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
Policlinico San Matteo Fondazione
2019-2024
University of Pavia
2017-2024
University of Florence
2023
University of Padua
2015
Not available.
The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes prefibrotic myelofibrosis (prePMF) as a distinct entity, characterized by well-defined histopathologic features together with minor clinical criteria (leukocytes, anemia, increased LDH, splenomegaly). aim the study was to examine relevance distinguishing prePMF from essential thrombocythemia (ET). We identified in our database all patients affected ET, and primary (PMF) diagnosed according...
Key Points Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m 2 , N -terminal type-B natriuretic peptide >1000 ng/L and/or >130 at diagnosis have poorer survival. Proteinuria >3.0 g/24 hours <35 identify patients high risk of progression to end-stage kidney failure. Prognostic stratification in can be easily made by staging systems, similarly AL transthyretin amyloidosis. Background The is involved almost 100% cases amyloidosis, a rare disease caused...
// Marco Pizzi 1,* , Francesco Piazza 2,3* Claudio Agostinelli 4 Fabio Fuligni Pietro Benvenuti 1 Elisa Mandato 2,3 Alessandro Casellato Massimo Rugge Gianpietro Semenzato and Stefano A. Pileri Department of Medicine, Surgical Pathology Cytopathology Unit, DIMED University Padua, Italy 2 Hematology Clinical Immunology Branch, 3 Venetian Institute Molecular Medicine (VIMM), Experimental, Hematopathology Sections, Diagnostic Specialty S. Orsola-Malpighi Hospital, Bologna, * These authors have...
IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) 1-2% per year. We analysed 176 consecutive patients MGUS evaluate factors for progression. With median follow-up 83 months (1214 person-years), 15 (8·5%) progressed WM (n = 14) marginal zone lymphoma 1). The rate was 1·32% year (95% confidence interval [CI] 0·80-2·20). serum protein concentration and the...
Not available.
Abstract Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on results ANDROMEDA study. However, real‐world data daratumumab efficacy in upfront therapy unselected scanty. In framework a prospective observational study, we investigated and safety 88 patients, including subjects IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered bortezomib 50 (56%) lenalidomide 31 (35%), monotherapy 7 (8%). The...
Background Early identification of immunoglobulin light-chain amyloidosis (AL) is crucial due to its rapid progression. Monoclonal (M-LC) testing the first step in diagnostic workup for patients with suspected cardiac (CA). We aimed determine whether time interval between CA suspicion and M-LC can be related AL survival outcomes.
Physical therapy is strongly recommended for patients with neurological disorders. Tai Chi-based treatments seem to improve physical functions like gait speed and balance. However, assessments after treatment rely on semi-quantitative clinical scales affected by subjectivity controversial results. This study aims at investigating whether Chi could be a valid alternative traditional physiotherapy rehabilitation. We propose wearable system composed of two inertial devices able objectively...
Current techniques of gait assessment rely on wearable sensors, pressure-sensitive walkway systems, and optical motion capture systems. A less invasive more portable solution could be represented by a mobile robot that follows the user during activity. The main idea behind this work relies finding best configuration for analysis with high acceptability from end users. To aim, two follow-me configurations have been designed: human-leader (i.e. person behind), robot-leader front). We asked 27...